

## Pharmacy & Therapeutics Update February 2019

For further information, contact [PTCommittee@stanfordhealthcare.org](mailto:PTCommittee@stanfordhealthcare.org)

### **Formulary Additions:**

#### **1. Cemiplimab (Libtayo®)**

- FDA-approved PD-1 inhibitor for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation
- Restrictions:
  - Outpatient setting for patients with locally advanced or metastatic cutaneous squamous cell carcinoma
- Must be approved by the patient's health insurance prior to treatment initiation

#### **2. Macimorelin (Macrelin®)**

- Oral growth hormone stimulation test for diagnosis of adult growth hormone deficiency
- Restrictions:
  - Outpatient use at Stanford Neuroscience Health Center
  - Prescribing authority restricted to neurosurgery and endocrinology
- Insurance authorization to be obtained prior to every patient appointment

### **Formulary Revisions:**

#### **1. Rivaroxaban (Xarelto®)**

- FDA-approved for coronary artery disease, peripheral artery disease, indefinite anticoagulation (reduced intensity dosing against VTE recurrence), non-valvular atrial fibrillation, DVT/PE treatment, and VTE prophylaxis in THA or TKA.
- Restriction criteria **to be removed**.

### **Formulary Deletions:**

#### **1. Nesiritide (Natreacor®)**

- The manufacturer is discontinuing production of the drug.